{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021809","form_type":"8-K","ticker":"ATRA","cik":"0001604464","company_name":"Atara Biotherapeutics, Inc.","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.625319+00:00","generated_at":"2026-06-15T02:33:26.290756+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Atara Biotherapeutics EVP Global Head of R&D Jakob Dupont resigns, enters consulting agreement","bullets":["Dr. Jakob Dupont, EVP Global Head of R&D, resigned effective May 12, 2023.","Entered consulting agreement through Dec 31, 2023; monthly fees $15,000 through Aug 31 then $4,500, plus $300/hr excess.","Outstanding equity awards will continue to vest during the consulting term."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021809","json":"https://secwatch.observer/filing/0000950170-23-021809.json","markdown":"https://secwatch.observer/filing/0000950170-23-021809.md","text":"https://secwatch.observer/filing/0000950170-23-021809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023021809/0000950170-23-021809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023021809/atra-20230512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:33:26.290756+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f729bea9a","claim":"Jakob Dupont resigned as Executive Vice President, Global Head of Research and Development at Atara Biotherapeutics, Inc..","evidence_excerpt":"On May 12, 2023, Dr. Dupont resigned from the Company and entered into a consulting agreement with the Company, pursuant to which Dr. Dupont will provide consulting services to the Company through December 31, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1604464/000095017023021809/0000950170-23-021809-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President, Global Head of Research and Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}